Global Search | Novartis

Sort by

Relevance

Newest first

Oldest first

Hide Filters

Showing 2757 results

Fixed-income securities
Press release / Dec 19, 2025

Novartis and US government reach agreement on lowering drug prices in the US

Novartis agrees to take actions aimed at meeting US Administration priorities for drug pricingAdditional Novartis medicines will be made available through direct-to-patient platforms in 2026Company…
Ad hoc release / Nov 24, 2025

Novartis receives FDA approval for Itvisma®, the only gene replacement therapy for children two years and older, teens, and adults with spinal muscular atrophy (SMA)

Ad hoc announcement pursuant to Art. 53 LR Itvisma (onasemnogene abeparvovec-brve) demonstrated improved motor function and stabilization in patients regardless of SMA treatment history in Phase III…
Careers
Press release / Mar 13, 2026

Novartis Cosentyx® receives FDA approval for pediatric patients aged 12+ with moderate to severe hidradenitis suppurativa

Cosentyx is the only IL-17A inhibitor approved for this population, and the first differentiated mechanism in nearly a decade1-3 HS often emerges around puberty, underscoring…
Clinical Trials / Mar 13, 2026

A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo
Clinical Trials / Mar 13, 2026

A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease
Clinical Trials / Mar 12, 2026

A Study to Investigate Efficacy and Safety of FWY003 Compared With Placebo in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration
Clinical Trials / Mar 05, 2026

Regulatory Post-Marketing Surveillance in Hidradenitis Suppurativa, Pediatric Plaque Psoriasis and JIA Treated With Cosentyx®(Secukinumab) in Korea
Clinical Trials / Mar 05, 2026

Real-world Use of Lutetium (177Lu) Vipivotide Tetraxetan in China(PSMAreal CN)